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ABSTRACT 
DESIGN AND SYNTHESIS STUDIES OF NEW  
S-ADENOSYL-L-METHIONINE ANALOGUES 
 
 by  
Shanshan Wu 
S-Adenosyl-L-Methionine (SAM), which is involved in methyl group transfers, is the 
second most abundant coenzyme in the human body. It is made from 
adenosinetriphosphate (ATP) and methionine catalyzed by adenosyltransferase. 
Methyltransferases (MTs) transfer the activated methyl group from the sulfur center to a 
specific position in a variety of substrates, e.g., DNA, RNA, proteins, and secondary 
metabolites. Methyltransferases have been linked to various diseases, including cancer.  
In recent years, more and more SAM analogues have been reported. These 
analogues show activities in biological target labeling. The purpose of this thesis is to 
design and synthesize new SAM analogues to inhibit cytosine DNA Methyltransferases 
in tumor cells. A series of target compounds was designed and synthesized in several 
steps from the starting material adenosine. The synthesis route has been divided into three 
parts: introduction of the nitrogen at the 5’ position, synthesis of aromatic aldehyde, and 
connection of these two compounds. More compounds with the same core structure will 
be designed and synthesized. The inhibition activities will be tested in future studies. 
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CHAPTER 1   
BACKGROUND 
1.1 Definitions 
S-Adenosyl-L-Methionine (Figure 1.1) (SAM) is the second most abundant coenzyme in 
the human body. SAM is involved in methyl group transfer reactions catalyzed by a variety 
of methyltransferases. SAM was first discovered in Italy by G. L. Cantoni in 1952 as an 
active methyl donor in nature. 
[1]
 It is formed enzymatically from L-methionine and 
adenosine triphosphate (Eq. 1.1). 
ATP + L-methionine + H2O SAM + PPi + Pi                                     (1.1) 
In vivo, the inorganic pyrophosphate (PPi) formed concomitantly with 
S-adenosylmethionine. PPi is hydrolyzed by pyrophosphatase to two equivalents of 
phosphates (Pi). Consequently, the synthesis of SAM is metabolically costly owing to 
consumption of all three phosphoryl groups of ATP. The enzyme that catalyzes the 























The stereochemical configuration at the sulfur in enzymatically formed S- 
adenosylmethionine is (S); however, S-adenosylmethionine spontaneously racemizes to 
the R isomer over a period of a few days. The carbons attached to the positively charged 
sulfur are electrophilic and readily transferred.  
The methyl group attached to the methionine sulfur atom in SAM is chemically 
reactive. This allows donation of this active methyl group from the sulfur center to a 
specific position in a variety of substrates, e.g., DNA, RNA, proteins, and secondary 
metabolites catalyzed by methyltransferases (MTs) (Eq. 1.2). More than 
40 metabolic reactions use this mechanism, and the product is S-adenosylhomocysteine 
















Figure 1.2.The structure of SAH. S-(5'-Deoxyadenos-5'-yl)-L-homocysteine. 
                                 SAH 






The intracellular SAM/SAH ratio is considered to be a regulator of the activity of these 
enzymes. The less the SAM/SAH ratio, the more tendency SAH binds and inhibits MTs. A 
dynamic balance exists between free SAH and bound SAH.  
This thesis is specifically concerned with DNA methyltransferases (DNMTs). All 



























There are five different DNMTs known in mammals: DNMT1, DNMT2, DNMT3a, 
DNMT3b and DNMT3L. DNMT1 (DNA cytosine-5-methyltransferase 1) is responsible 
for the maintenance of methylated DNA by copying DNA methylation patterns from the 
parental strand to the newly synthesized daughter strand during the DNA replication 
process. It helps regulate gene expression, genome imprinting, and x-chromosome 
inactivation. 
The catalytic mechanism for the methylation of cytosine-5 has been studied 
extensively, and is shown as Figure 1.3. The thiol group of a cysteine residue in the active 
site of DNMTs serves as a nucleophile that attacks the 6-position of cytosine to generate a 
covalent DNA-protein intermediate that possesses nucleophilic properties at the 5-position. 
This reactive intermediate accepts a methyl group from SAM to form the 5-methyl 
covalent adduct and SAH. Following the methyl transfer, the proton at the 5-position is 
abstracted by a basic residue in the active site of the enzyme that is later removed from the 
6-position by β-elimination to generate the methylated cytosine and the free enzyme. 
[2]
 
1.2 SAM Cycle 
One of the essential metabolic functions of the body is active methyl donation. The 







Figure 1.4. The SAM regeneration cycle.  
In the first step of this cycle, SAM is produced from methionine by the addition of 
ATP. After the methyl group has been donated, homocysteine remains. Because 
homocysteine has pro-oxidant properties (elevated levels are associated with 
cardiovascular disease), it must be detoxified. Two separate mechanisms exist, both of 
which are serine dependent. In the first mechanism, homocysteine is re-methylated by 
methyltetrahydrofolate (Me-THF, or ―activated‖ folic acid) back to methionine, and the 
SAM cycle is closed. Under most circumstances, this should be the dominant pathway. In 
the second mechanism, homocysteine is combined with serine to form cystathionine which 
is split back apart (slightly differently) to yield cysteine and homoserine. This reaction 
depends on the enzyme cystathionine beta-synthase which opens up the SAM cycle and 




SAM is a naturally occurring compound that is found in almost every tissue and fluid in the 





grams of SAM per day, primarily in the liver. SAM plays a role in the immune system, 
maintains cell membranes, and helps produce and break down brain chemicals, such as 
serotonin, melatonin, and dopamine. It works with vitamin B12 and folate (vitamin B6). 
Being deficient in either vitamin B12 or folate may reduce levels of SAM in the body. 
In the United States and Canada, SAM is sold as a nutritional supplement under the 
marketing name SAM-e (also spelled SAME or SAMe). Some research, including multiple 
clinical trials, has indicated taking SAM on a regular basis may help fight depression, 
[4]
 
liver disease, and the pain of osteoarthritis. 
[5] 
Formation of SAM is a major pathway in the metabolism of dietary methinone, 
which is a requirement for the growth of many tumour cells. Inhibitors of the polyamine 
biosynthetic enzyme S-adenosylmethionine decarboxylase have been investigated 
clinically in the contexts of anticancer and antiparasitic therapies. 
[6]
 
Epigenetic regulation involving SAM includes methylation at the 5’ position of 
cytosine in CpG dinucleotides, histones, and several nonhistone transcriptional regulators, 
such as the tumor suppressor protein p53 and the general transcriptional factor TAF10.
[7]
 It 
is a pivotal mechanism for the epigenetic regulation of gene expression. DNA methylation 
represses transcription and is essential for the maintenance of chromatin structure and 
genomic stability. Alterations of the promoter methylation have been associated with 
changes of transcription profiles of cancers. Research has shown that improper DNA 
methylation can either activate or inactivate a gene. If certain genes are activated when 
they are supposed to be inactive, or inactivated when they are supposed to be active, cancer 





Furthermore, methylation of homocysteine re-generates methionine. The methyl donor in 
this case is either betaine, which is derived from choline, or 5-methyl-tetrahydrofolate. 
Thus, the SAM/SAH ratio may also be tied to metabolism of phospholipids and folic acid. 
How the status of SAM/SAH, phospholipids, and folate may affect the life span, and 
whether such an effect contributes to epigenetic control are interesting questions, and they 
may turn out to be highly relevant to human health.    
Although the roles of SAM in cancer cells are not completely understood currently, 
studies have demonstrated that DNMTs are highly expressed in cancer cells. Inhibition of 
DNMTs has resulted in anti-cancer activities. More details will be discussed in section 1.5. 
1.4 SAM Analogues  
In recent years, many SAM analogues have been developed to label and identify biological 
targets, e.g., the SAM riboswitch aptamer and protein arginine methyltransferases, or to 
probe methylation patterns. 
[8][9] 
These compounds contain reactive functional groups that 
can be conjugated with reporters such as fluorophores (Figure 1.5). The compound on the 
left in Figure 1.5 demonstrated 2-fold higher binding over the original metabolite SAM 
toward the SAM riboswitch aptamer (the Kd of this compound is 3.1 μM, while that of 
SAM is 6.0 μM). This compound may constitute a novel antibiotic. In the second example, 
the researchers combined SAM analogues (the compounds on the right in Figure 1.5) with 
a protein-engineering approach to label and identify PRMT1 target in the context of a 
complex cellular mixture. The SAM-binding pocket of PRMT was modified to utilize a 































Figure 1.5. The structures of two new SAM analogues which have been reported, left: a 
new analogue targeting SAM riboswitch aptamer; right: SAM analogues labeling 
substrates of protein arginine methyltransferase.    
Another type of SAM analogues is N-chloromustard-substituted adenosines which 
were expected to react with the proteins that the analogues bind (Figure 1.6). 
[10] 
The reason 
to replace simple alkyl N-iodomustards by the chlorine analogues is the concern of the high 
reactivity of alkyl N-iodomustards. Although these nitrogen-containing SAM analogues 
did not react with the protein targets as expected, they were used for a detailed 





















Recently, a new advanced N-iodomustard SAM analogue has been reported. This SAM 
analogue (Figure 1.7) bears an azide group, which would be capable of undergoing the 
Staudinger ligation or copper-catalyzed azide−alkyne cycloaddition (CuAAC or Click) 
chemistry. This bifunctional molecule was designed to covalently label DNA and protein 
in a methyltransferase-dependent fashion. It was successfully synthesized and shown to be 
















Figure 1.7. The structure of an azide-bearing N-mustard SAM analogue. 
1.5 DNMT1 Inhibitors 
DNMT1 has been linked to various diseases including cancer. DNMT1 inhibitors are 
regarded as potential anticancer agents. Several DNMT1 inhibitors for the treatment of 
neoplastic diseases have been developed. Vidaza ® (azacitidine) and Dacogen ® 
(decitabine), which are irreversible, are among the new agents approved by the FDA for 
the treatment of myelodysplastic syndrome.
 [13]
 The structures of these two drugs are 
shown as Figure 1.8. These 5-azanucleoside analogues can be incorporated into DNA to 
replace cytidine and the absence of a hydrogen atom at the C5 position hinders DNMT 



























Figure 1.8. The structure of Vidaza® (azacitidine) and Dacogen® (decitabine) which are 



















Figure 1.9. The mechanism of 5-azanucleoside analogues induced degradation of 
DNMTs. 
Although many similar suicide inhibitors of DNMT1 have been developed, few 
reports on selective reversible DNMT1 inhibitors can be found in the literature. Recently, a 
series of Δ2-isoxazoline constrained analogues of procaine were prepared and their 
inhibitory activity against DNMT1 was tested by S. Castellano and her colleagues. Among 
these reversible inhibitors, derivative a (Figure 1.10) is the most potent drug in vitro (IC50 
= 150 μM) and it has been a novel lead compound for the development of non-nucleoside 
DNMT inhibitors. 
[14]
 The binding mode of derivative a with the enzyme was investigated 
by means of a simple competition assay as well as by docking simulations on to a 
crystallographic structure of human DNMT1.
 [14]
 The nitro group was shown to interact 





interaction between the phenyl ring of compound a and the DNMT1 binding pocket. This 



















CHAPTER 2  
PURPOSE AND DESIGN CONCEPT 
1.1 Purpose  
Cancer, known medically as a malignant neoplasm, is a broad group of various diseases, all 
involving unregulated cell growth. In 2007, cancer caused about 13% of all human deaths 
worldwide (7.9 million) and the rates are still rising.
[16]
 More and more anticancer drugs 
have been developed over the last three decades, such as Generic Cytosar (Cytarabine), 
Generic Eloxatin (Oxaliplatin). Many of the anticancer drugs are irreversible, which means 
they form covalent adducts with the molecular targets and the inhibition cannot be reversed. 
This irreversibility may result in high cellular toxicity. Therefore, reversible inhibition of 
targets in cancer cells is highly desirable.  
There is a lack of reports on the inhibition effect of SAM analogues on DNA 
methyltransferase. SAH is a known strong inhibitor of DNA methyltransferases at the 
SAM binding site. However, SAH-binding proteins are widely found in cells and it is 
unlikely to use SAH to selectively inhibit DNMTs. The purpose of this thesis is to design 
and synthesize a series of new SAM analogues to work as DNMT1 inhibitors. These 
analogues should fill the following requirements. First, they can specifically inhibit 
cytosine DNA methyltransferases, and have less activities on other similar targets, such as 
protein methyltransferases. The crystallographic structure of human DNMT1 is a very 
important tool to guide the design. Second, as mentioned before, reversible inhibition 
needs to be developed. The interactions between the ligands and the target may be 




2.1 Crystal Structure Study and Design Concept 
A combination of mechanism-based design (transition state inhibitor) and structural 
modifications was the basic design concept in this thesis. The crystal structures of DNA 
methyltransferases made a contribution to the understanding of the enzyme binding pocket. 
Based on the well-understood reaction mechanism, a lead SAM analogue was designed to 
mimic the reaction transition state while occupying the binding pocket. Then, a series of 
SAM analogues was also designed in succession by structural modifications. 
 
 
Figure 2.1. A cartoon of cytosine DNA methyltransfer process and the function of 
DNMT1 inhibitors.  
 
In the process of cytosine DNA methyl transfer, DNA binds to the DNMT1 pocket 
first through hydrogen-bonding and electrostatic interactions.
[17]
 The enzyme-DNA 
complex helps form the correct binding pocket for the free SAM. Then, the active enzyme 
can transfer the methyl group from the sulfur center to the 5’ position of cytosine. While it 




is likely for a small molecule (such as SAH) to enter the SAM binding site and restrict or 
slow the reaction, (Figure 2.1). 
There is more than one binding site within DNMT1. The one for SAM, and the one 
for the extrahelical cytosine of the duplex DNA are close to each other. It is possible to 
design an SAH analogue to occupy both pockets at the same time. In the process of DNA 
methylation, DNA binds to the enzyme first. There is a concern whether the SAH 
analogues would bind to the enzyme in its active conformation in the absence of the DNA 
which contains an extrahelical cytosine. Therefore, a superposition study of a bound SAH 
in free mDNMT1 and the productive covalent mDNMT1-DNA complex (Figure 2.3) is 
needed to evaluate the significance of the change .Crystal structures of DNMT 
co-crystallized with SAH shows that SAH undergoes a slight positional shift from the 
DNA-free state to its productive covalent complex with DNA. This slight positional shift is 
in response to the covalent link between Cys1229 and the flipped-out cytosine in a duplex 
DNA, and helps accommodate the newly added 5-methyl group. However, the overall 
structural change is so small that the SAH analogue would bind the protein active 
conformation whether the DNA is in the presence or not. Interactions between SAH and 








Figure 2.2. Left: Interactions between SAH and binding pocket residues in free mDNMT1 
(PDB: 3PT9). Right: Bound SAH in the productive covalent mDNMT1-DNA complex is 





Figure 2.3. Superposition of bound SAH in free mDNMT1 (blue color) and the productive 
covalent mDNMT1-DNA complex (pink color), using Alchemy. Superposed atoms are the 
sulfur atom and all the atoms of adenosine.   
 
A crystal structure containing a hemimethylated DNA trapped with DNMT and 
SAH was examined to facilitate the design. The unmethylated cytosine adopts an extra 
helical position to insert into a cytosine binding site that is in close proximity to the sulfur 
of SAH (Figure 2.4) The distance between the carbon at 5 position of cytosine and the 
sulfur atom of SAH is 4.5 Å. The flipped-out cytosine was stabilized by surrounding 




cytosine forms two hydrogen bonds with Arg 1313 and Arg 1315, and the 3-nitrogen forms 
hydrogen bond with Glu 1269. The 4-amino group forms hydrogen bond with Pro 1227. 
This result indicates that the carbonyl group, the 3-position nitrogen and the 4-position 




Figure 2.4. The crystal structure of SAH and Human DNMT1-DNA complex (PDB: 
4DA4), using SYBYL-X1.3. SAH1701 in chain A, Cytosine4918 in chain D, and parts of 






Figure 2.5. The flipped-out cytosine is stabilized by surrounding residues in the active site 
of the enzyme. 
[18] 
 
A transition state analogue was designed to occupy the SAM binding site and the 
cytosine binding site simultaneously and force the cytosine to adopt an intrahelical 
position. After the crystal structure studies, it was decided that part of the SAM core 
structure was to be kept and part to be deleted.  
First, adenosine and the long chain should be kept. As Figure 2.2 shows, SAH can 
form several hydrogen bonds with the amino acid residues at the binding site of DNMT1, 
such as Glu 1171, Met 1172, Leu 1154, Val 1582, Gly 1153.  Therefore, to maintain these 
interactions between DNMT1 and SAM analogues, the adenosine and carboxyl group with 
the long chain should be kept. Second, to be a good inhibitor, extra binding interactions 
other than the ones involving SAH are required. The process of DNA cytosine methylation 




introducing a cytosine to the SAM analogue may enhance binding by taking advantages of 
the interactions between cytosine and cytosine-binding side chains. To simplify the 
synthesis, it was decided to use isocytosine to take the place of the cytosine which is 
connected to the sulfur atom.  The hydrogen bonding sites on the cytosine base may be 
necessary to enhance binding, despite still being a hypothesis. Other functionalized 
aromatic rings (benzene or heterocyclic rings) may also be used to play the same role as the 
cytosine. Third, the sulfur atom with positive charge can be changed to a nitrogen atom, 
which is expected to be protonated under physiological conditions. Fourth, the α-amino 
group of SAM can be removed because it is not involved in any interaction with the protein, 

















Figure 2.6. Design of a transition state inhibitor of DNMT.  
In summary, the design of SAM analogues was inspired by the catalytic mechanism 
of DNMT and the classic DNMT inhibitors like Vidaza® (azacitidine) and Dacogen® 
(decitabine). In addition, the study of the crystal structure of DNMT/DNA/SAM complex 
made a contribution. The first target compound (compound A) is shown as Figure 2.6. 




substitutes of the 5’-amine, (Figure 2.7). The electrostatic potential maps of these 












R1 B: R1=H, R2=H





Figure 2.7. Structures of compounds B, C, D, and E.  
The equilibrium geometry was calculated with Hartree-Fock 6-31G*. Compare to 
the isocytosine, the electrostatic map of 2-Methyl-5-nitro-phenol is the most similar one 
among the others. The carbonyl group of isocytosine and the nitro group of 
2-Methyl-5-nitro-phenol are both negative (-210-- -150 kcal). Moreover, the hydrogen on 
the hydroxyl group and the one on the amino group of isocytosine are both within the range 
of 150--332 kcal. That indicates that both hydroxyl group and nitro group may have the 
same interactions with the enzyme binding sites as the carbonyl group and the amino group 
of isocytosine. The surface areas of these four compounds are 166.5 Å, 161.2 Å, 140.1 Å, 
141.1Å, respectively. The surface area of ortho-creasol is the closest to isocytosine. The 
role of the substituted groups of the benzyl ring and isocytosine needs to be verified in 





Figure 2.8. The electrostatic potential maps of A, C, D, and E (calculated using 
Spartan'10). Calculated equilibrium geometry with Hartree-Fock 6-31G*. Color code: 
red( -210—  -150 kcal), orange ( -150—  80 kcal), yellow ( -80—  -20 kcal), green 
( -20—150 kcal),    blue ( 150—332 kcal). 
  























































Figure 3.1. Retrosynthetic analysis of target compound, which was divided into three parts: 





The synthesis route of compound A has been divided into three parts using retrosynthetic 
analysis (Figure 3.1): introduction of the nitrogen at the 5’ position (compound 5), 
synthesis of protected isocytosine acetaldehyde (compound 8) from iso-cytosine, and 
connection of compound 5 and 8. Compound 5 was made from methyl-4-oxobutanoate and 
amine 4. The synthesis routes are shown as Scheme 3.1, 3.4 and 3.6, respectively.   






















































Scheme 3.1. Synthesis route of compound 5 (a) Acetone, p-TsOH, RT., overnight, 51%. (b) 
CH2Cl2, EtN3, MsCl, RT. 1hr, 81%. (c) NaN3, DMF, 70 ° C, 48hr, 68%. (d) H2, 10% Pd/C, 
EtOH, RT.,overnight, 89%. (e) NaBH3CN, AcOH, methyl-4-oxobutanoate, RT. 1.5 hr, 
23%. 
Introduction of the amino group is the key reaction in the first part of the synthesis. 
Based on some reported reactions, reductive amination was chosen to introduce the 
complete N-substituent on the 5’-position.
[10]
 Starting from commercially available 




the corresponding acetonide. Acetone was used as both the solvent and the reactant. It was 
found that maintaining acetone under anhydrous condition was critical to the reaction 
yields. There are several kinds of desiccants used in the lab, namely, potassium carbonate, 
magnesium sulfate, and Drierite® (calcium sulfate). Potassium carbonate was used to dry 
acetone in the first attempt. However, it was found that potassium carbonate absorbed 
moisture from the air too fast, which as a result gave very poor yield (less than 20%). 
Finally, anhydrous acetone was successfully prepared by distillation over Drierite®.  
After the acetonide was installed, a leaving group was introduced by transforming 
the free 5’-hydroxy group of the 2’, 3’-O-isopropylideneadenosine (1) into a mesylate ester 
(2) using MsCl in the presence of triethylamine. Subsequent displacement could not be 
achieved by reacting with ethyl 4-aminobutanoate hydrochloride, as planned at the 




















Scheme 3.2. Supposed reaction which did not work using ethyl 4-aminobutanoate 
hydrochloride, DCM, 24 hr. 
 
TLC analysis of the reaction indicated too many products that would be difficult 




amount of mesylate coexists with the secondary amine product, which could further react 
to form the tertiary amine. 
Instead, the 5’ nitrogen was introduced using sodium azide in DMF under reflex 
condition for 48 hr, followed by reduction to give amine 4 in 49.7% yield over  three steps. 
At first, the 6-amino group of adenosine was thought to require protection. But this method 
was discarded due to its low yield (less than 20%) and the difficulty in the subsequent 























Scheme 3.3. Protection of the 6-amino group of adenosine. 
However, amine 4 could be subjected to a direct condensation with 
methyl-4-oxobutanoate. The exocyclic amino group of adenosine is much less reactive 
than the primary aliphatic amine. The aliphatic amine easily reacted with aldehyde, 
although a problem was found in controlling the quantity of methyl-4-oxobutanoate. As a 
result, a mixture of the desired product (5) and the 2 equiv. condensation byproduct (Figure 
















Figure 3.2. The byproduct of reaction e. 
In sum, for the first part of the synthesis, compound 5 was made from adenosine in 
five steps (Scheme 1): protection of the 2’-and the 3’-hydroxyl groups, introduction of a 
leaving group to the 5’-hydroxy group, introduction of the 5’ nitrogen using sodium azide, 
followed by reduction to give amine, and reaction with aldehyde.  

































Scheme 3.4. Supposed synthesis route of compound 8 (a) phthalic anhydride, pyridine, 
reflux, 24hr , 46% (b)NaH, 2-bromomethyl-1,3-dioxalane, pyridine, reflux, 24 hr, 64% (c) 
MeOH, p-TsOH, RT., overnight,  unexpected product. 
It was more difficult to carry out the second part synthesis due to the following 




Several solvents were tried, such as DMF, pyridine, and THF. The results showed that 
pyridine was better than the others, but still required a high temperature (140 °C) to 
completely dissolve isoC.  
Second, the amino group of isoC needs to be protected to avoid intramolecular 
condensation after the aldehyde is introduced. Ac2O was tried at the beginning using 
pyridine as a solvent. However, it was difficult to control the quantity of the acetate groups 
to avoid insufficient N-acetylation or overreaction on the oxygen of isoC. Then, phthalic 
anhydride was chosen to be the protecting group, and the reaction conditions were shown 
in Scheme 3.4.   
Third, instead of forming the aldehyde, the dioxalane may have spontaneously 
cyclized with the adjacent phthalimide over a period of a few days or less than one day 
under the acid conditions in the presence of MeOH, (8) 
Therefore, this synthesis route of compound 8 was abandoned due to the 
incompatibility between the amino group and the aldehyde group. As the alternatives, 
phenylacetaldehyde and 4-nitrophenylacetaldehyde were used to replace 8 to connect with 
compound 5. The structures of phenylacetaldehyde, 4-nitrophenylethanol and other similar 


















Figure 3.3. Aromatic molecules used to replace isoC part. Left to right: 
phenylacetaldehyde; 4-nitrophenylacetaldehyde, which can be synthesized from 
4-nitrophenylethanol; 2-(2-hydroxyphenyl) acetaldehyde, which can be synthesized from 
2-hydroxyphenethyl alcohol; 2-(2-hydroxyphenyl, 4-nitro)-acetaldehyde which can be 
synthesized from 2-(2-hydroxyphenyl, 4-nitro)-alcohol. 
 
Phenylacetaldehyde is commercially available, and it can be directly conjugated to 
compound 5, while 4-nitrophenylacetaldehyde needs to be synthesized by oxidation from 
4-nitrophenylethanol, shown as Scheme 3.5. The original PCC oxidation was tried at the 
beginning. Two products were obtained after this reaction, which could not be identified. 
NMR showed that one product had no aldehyde peak at around 9-10 ppm, and the other did 
have one peak at around 10 ppm. However, the latter compound was lack of the expected 
CH2 peaks at around 3-4 ppm but showed an extra CH2 peak at around 2 ppm which implies 
that the aromatic ring may have undergone some unknown transformations.  
Swern oxidation was also attempted using oxalyl chloride in DMSO. This reaction 
did not afford 4-nitrophenylacetaldehydealdehyde either. Then, PCC oxidation with silica 




attribute to the fact that silica gel can absorb water from the reaction, or it helps the reaction 




Swern oxidation or 
PCC oxidation
 
Scheme 3.5. Swern and PCC oxidation of 4-nitrophenylethanol. PCC oxidation: DCM, 
PCC (2 equiv.), RT., 3 hr. Swern oxidation: DMSO, DCM, TEA, oxalyl chloride (1.2 
equiv.), -78°C to R.T., 2 hr.   
3.3 Synthesis Part3 
Phenylacetaldehyde easily reacted with compound 5 via the same procedure as the 
reductive amination in part1, affording a yield of 92%. After 2 steps of deprotection by acid 
and base, one after another, the final compound B was obtained, shown as Scheme 3.6. The 
synthesis of compounds C, D and E are under way following the same procedure as was 





























































B, C, D, E
 
Scheme 3.6. Synthesis route of part 3. (a) NaBH3CN, AcOH, RT. 1.5hr (b) p-TsOH ·H2O 






CHAPTER 4  
EXPERIMENTAL INFORMATION 
 











To a suspension of adenosine (1.0 g, 3.74 mmol) in dry acetone (200 ml) was added 
41.14mmol of dry p-TsOH (7.1 g, 11 equiv.) in one portion. The mixture was stirred under 
an atmosphere of Ar at room temperature overnight. The mixture was concentrated under 
reduced pressure. The residues were stirred with 250 ml Sat. NaHCO3 solution for 6 hr and 
then extracted with ethyl acetate three times. The organic layer was dried over MgSO4 and 
then filtered. The solvent was evaporated and the crude product was purified by column 
chromatography (dichloromethane/methanol 20:1, silica). After drying under vacuum, a 
white solid was obtained (0.582g, 51%): 
1
H NMR (CDCl3) δ8.31(s, 1H), 7.84(s, 1H), 
6.40(m, 1H), 5.84(m, 1H), 5.72(m, 1H), 5.20(m, 1H), 5.12(m, 1H), 4.53(m, 1H), 3.94(m, 
1H), 1.63(s,3H), 1.36(s, 3H) 
















A solution of 0.53 mmol of 2’,3’-O-isopropylideneadenosine (162 mg 1.0 equiv.) in 7.5 ml 
of dichloromethane was flushed with Ar before 162 μL of triethylamine (1.17 mmol, 2.4 
equiv.) and 50 μL mesylchloride (0.64 mmol, 1.2 equiv.) were added.[12]
 
Solution was 
stirred at room temperature 1hr and then 7.5 mL of saturated NaHCO3 solution was added. 
The layers were separated and the organic layer was washed two times with 7.5 mL NaCl. 
The combined aqueous layers were re-extracted with CH2Cl2 (2 x 5ml) and the combined 
organic layers were dried over MgSO4. The solids were filtered off and the solvent was 
evaporated. The crude product weight 167 mg of the mesylate (0.43 mmol, 81 %) as a 
colourless foam. The product was directly used for the next reaction without purification 
















 A mixture of 2, (167 mg, 0.397 mmol) and sodium azide (260 mg, 3.97 mmol, 10 equiv.) 
was suspended in anhydrous DMF (6 ml). The reaction was heated at 70 °C for 48 hr. 
[19]
 
The mixture was filtered, and evaporated under reduced pressure. DMF was removed in 
vacuo. The residue was purified by silica gel chromatography, (dichloromethane/ methanol 
20:1). Light yellow syrup (90 mg, 68.2%) was obtained. 
1
H NMR (CDCl3) δ8.25(s, 1H), 
7.92(s, 1H), 6.12(s, 1H), 5.95(s, 1H), 5.50(m, 1H), 5.12(m, 1H), 4.38(m, 1H), 3.60(m, 1H), 

















Compound 3 (40 mg) was dissolved in 5 ml anhydrous ethanol, 15 mg of 10% Pd/C was 
added. The reaction mixture was placed under vacuum and then under an atmosphere of H2 
at room temperature overnight. The mixture was filtered, and evaporated under reduced 
pressure. The residue was purified by silica gel chromatography, (dichloromethane/ 
methanol 10:1). Compound 4 (33 mg) of was obtained in 89.2% yield.
 1
H NMR (CDCl3) 
δ8.36(s, 1H), 8.15(s, 1H), 6.15(s, 1H), 5.50(m, 1H), 5.05(m, 1H), 4.20(m, 1H), 3.30(m, 















NaBH3CN 6.8 mg (0.108 mmol, 1equiv.) and AcOH 5.57 μl (0.097 mmol, 0.9 equiv.) were 
added to a solution of 33 mg of compound 4 (0.108 mmol, 1 equiv.) and 0.01 mL of 
methyl-4-oxobutanoate (0.097 mmol, 0.9 equiv.) in 1 mL MeOH. The reaction mixture 




sat. NaHCO3 (aq.), the organic layer was washed with NaHCO3, dried over MgSO4, and 
then evaporated under reduced pressure. 
[12] 
The residue was purified by silica gel 
chromatography, (dichloromethane/ methanol 50:1). Compound 5 (10 mg) was obtained in 
22.8% yield.
 1
H NMR (CDCl3) δ8.25(s, 1H), 7.80(s, 1H), 5.90(s, 1H), 5.64(s, 1H), 5.38(m, 
1H), 4.95(m, 1H), 4.26(m, 1H), 3.58(m, 3H), 2.80(m, 2H), 2.50(m, 2H), 2.20(m, 2H), 
1.78(m, 2H), 1.54(s, 3H), 1.26(s, 3H). 
13
C NMR (CDCl3) δ: 173.2, 155.5, 153.0, 146.5, 




















A mixture of iso-cytosine, (111 mg, 1 mmol) and phthalic anhydride (148 mg, 1 mmol, 
1equiv.) was suspended in anhydrous pyridine (15 ml). The reaction was heated at 140 °C 
for 24 hr. Pyridine was removed in vacuo reduced pressure. The residue was purified by 
silica gel chromatography, (dichloromethane/ methanol 50:1). White foam (110 mg, 45.9%) 
was obtained. 
1
H NMR (CDCl3) δ8.18 (s, 1H), 7.72 (m, 2H), 7.54 (m, 1H), 6.50 (s, 1H), 












 Compound 6 (110 mg, 0.458 mmol) was dissolved in 5 ml dry pyridine was added sodium 
hydride (10 mg, 60% in oil), and the mixture was stirred for 1 hr at room temperature. The 
reaction mixture was heated to 110 °C and a solution of 2-bromomethyl-1,3-dioxalane (70 
μL) was added in several portions over 24 hr. 
[20]
 Pyridine was removed under reduced 
pressure. The residue was purified by silica gel chromatography, (dichloromethane/ 
methanol 100:1). Colorless syrup (78 mg, 64%) was obtained.  .  
1
H NMR (CDCl3) δ8.55 (s, 








PCC oxidation: 4-nitrophenylethanol (100 mg, 0.6 mmol), was dissolved in 10 ml MeOH. 
PCC (156 mg, 1.2 equiv.) was added at first, and the mixture was stirred at RT. for 1.5 hr. 
After checked TLC, another 104 mg of PCC was added, and the reaction was continued for 
another 1.5 hr. The residues were diluted with 20 ml of dichoromethane and washed with 
3x10 ml of sat. NaHCO3 solution. The organic layer was dried over MgSO4 and then 
filtered. The solvent was evaporated and the crude product was purified by column 
chromatography (Haxane/ EA= 4:1, silica). After drying under vacuum, a white solid 
compound was obtained. 
Swern oxidation: A solution of anhydrous DMSO (3 mL) in CH2Cl2 (3 mL) was 
added slowly dropwise to stirred solution of oxalyl chloride (1.218 mmol, 150 μL) in 
CH2Cl2 (3 mL) at -78 °C. After the addition was complete, the solution was stirred for 5 
min, and then, 4-nitrophenylethanol (200 mg, 1.2 mmol) in CH2Cl2 (3 mL) was added (15 
min). The solution was stirred for 20 min. Anhydrous NEt3 (4 mL) was slowly added 
dropwise. The reaction was let warm to R.T. for 2hr, and then, poured into 50 mL of water. 
It was washed with 3x30 mL CH2Cl2, and then the organic layer was dried over MgSO4, 




column chromatography (Haxane/ EA= 2:1, silica). After drying under vacuum, a red 














NaBH3CN 2.5 mg (0.04 mmol, 1 equiv.) and AcOH 2.30 μl (0.04 mmol, 1 equiv.) were 
added to a solution of 20 mg of compound 5 (0.04 mmol, 1 equiv.) and extra Phenyl 
acetaldehyde (14 μl, 3 equiv.) in 5 ml MeOH. The reaction mixture was stirred at room 
temperature 1.5 hr. After diluting the reaction mixture with ethyl acetate and sat. NaHCO3 
(aq.), the organic layer was washed with NaHCO3, dried over MgSO4, and then evaporated 
under reduced pressure. The residue was purified by silica gel chromatography, 
(dichloromethane/ methanol 50:1).  A colorless syrup compound 9 (22 mg, 92%) was 
obtained.
 1
H NMR (CDCl3) δ8.35(s, 1H), 7.92(s, 1H), 7.15(m, 5H), 6.06(s, 1H), 5.76(s, 
1H), 5.54(s, 1H), 4.98(s, 1H), 4.30(s, 1H), 3.65(m, 3H), 2.76(m, 6H), 2.55(m, 2H), 2.28(m, 
2H), 1.84(m, 2H), 1.56(s, 3H), 1.30(s, 3H). 
13
C NMR (CDCl3) δ:174.1, 155.5, 153.0, 146.1, 
140.0, 128.7, 128.4, 125.9, 114.3, 91.1, 83.7, 83.2, 56.2, 55.8, 53.3, 51.5, 33.1, 31.5, 29.7, 

























To a suspension of compound 9 (18 mg), in a mixture of MeOH/ H2O= (10:1, 3 mL: 0.3 
mL), was added 40 mg of p-TsOH in one portion. The mixture was stirred at room 
temperature overnight, and then concentrated under reduced pressure. The residues were 
washed with 3x40 mL sat. NaHCO3 solution. The organic layer was dried over MgSO4 and 
then filtered. A colorless syrup (10 mg) was obtained, yield in 71%. The product was 














To a suspension of compound 9 (10 mg), in a mixture of MeOH/H2O= (10:1, 3 mL: 0.3 
mL), was added 30 mg of KOH in one portion. The mixture was stirred at room 
temperature overnight, and then concentrated under reduced pressure. The residue was 
purified by silica gel chromatography, (dichloromethane/ methanol 1:1). A colorless syrup 
(4 mg, 40%) was obtained.
1




6.01(s, 1H), 4..75(s, 1H), 4.35(s, 1H), 4.15(s, 1H), 3.18(m, 2H), 2.89(m, 2H), 2.76(m, 5H), 





CHAPTER 5  
CONCLUSIONS AND FUTURE STUDIES 
 
In summary, a series of SAM analogues was designed using a combination of 
mechanism-based design (transition state inhibitor) and structural modifications. The 
analogues were expected to inhibit cytosine DNA Methyltransferases. Among these 
analogues, compound B was synthesized successfully in eight steps from the starting 
material adenosine. The synthesis of other compounds is under way following the same 
procedure as for the synthesis of compound B. 
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